Kees Been is currently the CEO at Lysosomal Therapeutics, a biotech company focused on leveraging the genetic implications of various lysosomal enzymes in neurodegenerative diseases, specifically concentrated on quickly moving into the clinic with novel drug compounds to establish target engagement in “genetic” PD patients carrying the GBA1 mutation. Kees was formerly the President and CEO of EnVivo Pharmaceuticals; He led EnVivo for eight years from an early-stage start-up to a respected CNS company with a broad pipeline of NCE drug compounds, its lead compound in a phase 3 program for Alzheimer’s disease and schizophrenia. 

​

LinkedIn